Non-coding RNAs in castration-resistant prostate cancer

Regulation of androgen receptor signaling and cancer metabolism

Jing Wen Shih, Ling Yu Wang, Chiu Lien Hung, Hsing-Jien Kung, Chia Ling Hsieh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a bone-metastatic status with no cure. Understanding of the molecular mechanisms conferring resistance to androgen deprivation therapy has the potential to lead to the discovery of novel therapeutic targets for type of prostate cancer with poor prognosis. Progression to castration-resistant prostate cancer (CRPC) is characterized by aberrant androgen receptor (AR) expression and persistent AR signaling activity. Alterations in metabolic activity regulated by oncogenic pathways, such as c-Myc, were found to promote prostate cancer growth during the development of CRPC. Non-coding RNAs represent a diverse family of regulatory transcripts that drive tumorigenesis of prostate cancer and various other cancers by their hyperactivity or diminished function. A number of studies have examined differentially expressed non-coding RNAs in each stage of prostate cancer. Herein, we highlight the emerging impacts of microRNAs and long non-coding RNAs linked to reactivation of the AR signaling axis and reprogramming of the cellular metabolism in prostate cancer. The translational implications of non-coding RNA research for developing new biomarkers and therapeutic strategies for CRPC are also discussed.

Original languageEnglish (US)
Pages (from-to)28943-28978
Number of pages36
JournalInternational Journal of Molecular Sciences
Volume16
Issue number12
DOIs
StatePublished - Dec 4 2015

Fingerprint

Untranslated RNA
Castration
Androgen Receptors
metabolism
RNA
Metabolism
Prostatic Neoplasms
cancer
Long Noncoding RNA
Neoplasms
Biomarkers
MicroRNAs
Refractory materials
Androgens
Hormones
Bone
therapy
deprivation
Therapeutics
hormones

Keywords

  • Androgen receptor
  • Cancer metabolism
  • Castration-resistant prostate cancer
  • Long non-coding RNAs
  • Micro RNAs
  • Non-coding RNA

ASJC Scopus subject areas

  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Spectroscopy
  • Inorganic Chemistry
  • Catalysis
  • Molecular Biology
  • Computer Science Applications

Cite this

Non-coding RNAs in castration-resistant prostate cancer : Regulation of androgen receptor signaling and cancer metabolism. / Shih, Jing Wen; Wang, Ling Yu; Hung, Chiu Lien; Kung, Hsing-Jien; Hsieh, Chia Ling.

In: International Journal of Molecular Sciences, Vol. 16, No. 12, 04.12.2015, p. 28943-28978.

Research output: Contribution to journalArticle

@article{a05cc900a90c4492b336c0e2b5780d69,
title = "Non-coding RNAs in castration-resistant prostate cancer: Regulation of androgen receptor signaling and cancer metabolism",
abstract = "Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a bone-metastatic status with no cure. Understanding of the molecular mechanisms conferring resistance to androgen deprivation therapy has the potential to lead to the discovery of novel therapeutic targets for type of prostate cancer with poor prognosis. Progression to castration-resistant prostate cancer (CRPC) is characterized by aberrant androgen receptor (AR) expression and persistent AR signaling activity. Alterations in metabolic activity regulated by oncogenic pathways, such as c-Myc, were found to promote prostate cancer growth during the development of CRPC. Non-coding RNAs represent a diverse family of regulatory transcripts that drive tumorigenesis of prostate cancer and various other cancers by their hyperactivity or diminished function. A number of studies have examined differentially expressed non-coding RNAs in each stage of prostate cancer. Herein, we highlight the emerging impacts of microRNAs and long non-coding RNAs linked to reactivation of the AR signaling axis and reprogramming of the cellular metabolism in prostate cancer. The translational implications of non-coding RNA research for developing new biomarkers and therapeutic strategies for CRPC are also discussed.",
keywords = "Androgen receptor, Cancer metabolism, Castration-resistant prostate cancer, Long non-coding RNAs, Micro RNAs, Non-coding RNA",
author = "Shih, {Jing Wen} and Wang, {Ling Yu} and Hung, {Chiu Lien} and Hsing-Jien Kung and Hsieh, {Chia Ling}",
year = "2015",
month = "12",
day = "4",
doi = "10.3390/ijms161226138",
language = "English (US)",
volume = "16",
pages = "28943--28978",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - Non-coding RNAs in castration-resistant prostate cancer

T2 - Regulation of androgen receptor signaling and cancer metabolism

AU - Shih, Jing Wen

AU - Wang, Ling Yu

AU - Hung, Chiu Lien

AU - Kung, Hsing-Jien

AU - Hsieh, Chia Ling

PY - 2015/12/4

Y1 - 2015/12/4

N2 - Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a bone-metastatic status with no cure. Understanding of the molecular mechanisms conferring resistance to androgen deprivation therapy has the potential to lead to the discovery of novel therapeutic targets for type of prostate cancer with poor prognosis. Progression to castration-resistant prostate cancer (CRPC) is characterized by aberrant androgen receptor (AR) expression and persistent AR signaling activity. Alterations in metabolic activity regulated by oncogenic pathways, such as c-Myc, were found to promote prostate cancer growth during the development of CRPC. Non-coding RNAs represent a diverse family of regulatory transcripts that drive tumorigenesis of prostate cancer and various other cancers by their hyperactivity or diminished function. A number of studies have examined differentially expressed non-coding RNAs in each stage of prostate cancer. Herein, we highlight the emerging impacts of microRNAs and long non-coding RNAs linked to reactivation of the AR signaling axis and reprogramming of the cellular metabolism in prostate cancer. The translational implications of non-coding RNA research for developing new biomarkers and therapeutic strategies for CRPC are also discussed.

AB - Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a bone-metastatic status with no cure. Understanding of the molecular mechanisms conferring resistance to androgen deprivation therapy has the potential to lead to the discovery of novel therapeutic targets for type of prostate cancer with poor prognosis. Progression to castration-resistant prostate cancer (CRPC) is characterized by aberrant androgen receptor (AR) expression and persistent AR signaling activity. Alterations in metabolic activity regulated by oncogenic pathways, such as c-Myc, were found to promote prostate cancer growth during the development of CRPC. Non-coding RNAs represent a diverse family of regulatory transcripts that drive tumorigenesis of prostate cancer and various other cancers by their hyperactivity or diminished function. A number of studies have examined differentially expressed non-coding RNAs in each stage of prostate cancer. Herein, we highlight the emerging impacts of microRNAs and long non-coding RNAs linked to reactivation of the AR signaling axis and reprogramming of the cellular metabolism in prostate cancer. The translational implications of non-coding RNA research for developing new biomarkers and therapeutic strategies for CRPC are also discussed.

KW - Androgen receptor

KW - Cancer metabolism

KW - Castration-resistant prostate cancer

KW - Long non-coding RNAs

KW - Micro RNAs

KW - Non-coding RNA

UR - http://www.scopus.com/inward/record.url?scp=84949437861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949437861&partnerID=8YFLogxK

U2 - 10.3390/ijms161226138

DO - 10.3390/ijms161226138

M3 - Article

VL - 16

SP - 28943

EP - 28978

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

ER -